1. In Vivo

Civil Society Groups Use COVID To Build Stronger Narrative For Equal Access

 
• By Ed Silverman

The divide between developed and developing countries for access to health care innovations has been spotlighted by the ongoing COVID-19 pandemic. Civil society groups pile on the pressure.

civil society concept
• Source: Alamy

The first hint that civil society groups were making a huge difference came last April. US Trade Representative Katherine Tai spoke at a closed-door meeting hosted by the World Trade Organization to discuss increased production and equitable access for COVID-19 vaccines. Among those attending were representatives from dozens of other governments and many large drug makers, which were wrestling with a contentious proposal to temporarily waive intellectual property protection for patents industrial designs, copyrights and protection of trade secrets, among other things.

Until then, there was no indication that the Biden administration would support the effort. But what Tai said stunned the...

More from COVID-19

More from In Vivo

Turning Defense Into Attack: Snapshots Of A Changing Medtech Market And How To Respond

 
• By Ashley Yeo

Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.

AI Agents Set To Reshape Biopharma’s Workforce And Operations

 
• By David Wild

While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.

MitoRx’s Muscle-Preserving Obesity Drug Takes Aim At GLP-1 Limitations

 
• By Jo Shorthouse

UK biotech targets the root cause of metabolic disease while preserving muscle mass in a crowded obesity market.